These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 25119106)
1. The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation. Liu X; Yuan H; Peres L; Chen S; Chen Z; de The H; Zhou J; Zhu J PLoS One; 2014; 9(8):e104906. PubMed ID: 25119106 [TBL] [Abstract][Full Text] [Related]
2. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. Ablain J; Leiva M; Peres L; Fonsart J; Anthony E; de Thé H J Exp Med; 2013 Apr; 210(4):647-53. PubMed ID: 23509325 [TBL] [Abstract][Full Text] [Related]
3. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Isakson P; Bjørås M; Bøe SO; Simonsen A Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048 [TBL] [Abstract][Full Text] [Related]
4. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820 [TBL] [Abstract][Full Text] [Related]
5. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Zhong S; Delva L; Rachez C; Cenciarelli C; Gandini D; Zhang H; Kalantry S; Freedman LP; Pandolfi PP Nat Genet; 1999 Nov; 23(3):287-95. PubMed ID: 10610177 [TBL] [Abstract][Full Text] [Related]
6. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology. Zhu G Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507 [TBL] [Abstract][Full Text] [Related]
7. PML-RARA fusion transcripts in irradiated and normal hematopoietic cells. Quina AS; Gameiro P; Sá da Costa M; Telhada M; Parreira L Genes Chromosomes Cancer; 2000 Nov; 29(3):266-75. PubMed ID: 10992301 [TBL] [Abstract][Full Text] [Related]
8. Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation. Yang S; Jeong JH; Brown AL; Lee CH; Pandolfi PP; Chung JH; Kim MK J Biol Chem; 2006 Sep; 281(36):26645-54. PubMed ID: 16835227 [TBL] [Abstract][Full Text] [Related]
9. Role of the promyelocytic leukaemia protein in cell death regulation. Salomoni P; Dvorkina M; Michod D Cell Death Dis; 2012 Jan; 3(1):e247. PubMed ID: 22237204 [TBL] [Abstract][Full Text] [Related]
10. PML::RARA and GATA2 proteins interact via DNA templates to induce aberrant self-renewal in mouse and human hematopoietic cells. Katerndahl CDS; Rogers ORS; Day RB; Xu Z; Helton NM; Ramakrishnan SM; Miller CA; Ley TJ Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2317690121. PubMed ID: 38648485 [TBL] [Abstract][Full Text] [Related]
11. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. Kamashev D; Vitoux D; De Thé H J Exp Med; 2004 Apr; 199(8):1163-74. PubMed ID: 15096541 [TBL] [Abstract][Full Text] [Related]
12. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980 [TBL] [Abstract][Full Text] [Related]
13. Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia. Grimwade D; Solomon E Curr Top Microbiol Immunol; 1997; 220():81-112. PubMed ID: 9103677 [TBL] [Abstract][Full Text] [Related]
14. Acute promyelocytic leukemia cases with nonreciprocal PML/RARa or RARa/PML fusion genes. Lafage-Pochitaloff M; Alcalay M; Brunel V; Longo L; Sainty D; Simonetti J; Birg F; Pelicci PG Blood; 1995 Mar; 85(5):1169-74. PubMed ID: 7858248 [TBL] [Abstract][Full Text] [Related]
15. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046 [TBL] [Abstract][Full Text] [Related]
16. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation. Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343 [TBL] [Abstract][Full Text] [Related]
17. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. Dos Santos GA; Kats L; Pandolfi PP J Exp Med; 2013 Dec; 210(13):2793-802. PubMed ID: 24344243 [TBL] [Abstract][Full Text] [Related]
18. A sumoylation site in PML/RARA is essential for leukemic transformation. Zhu J; Zhou J; Peres L; Riaucoux F; Honoré N; Kogan S; de Thé H Cancer Cell; 2005 Feb; 7(2):143-53. PubMed ID: 15710327 [TBL] [Abstract][Full Text] [Related]
19. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926 [TBL] [Abstract][Full Text] [Related]
20. The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha. Occhionorelli M; Santoro F; Pallavicini I; Gruszka A; Moretti S; Bossi D; Viale A; Shing D; Ronzoni S; Muradore I; Soncini M; Pruneri G; Rafaniello P; Viale G; Pelicci PG; Minucci S Leukemia; 2011 May; 25(5):814-20. PubMed ID: 21331069 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]